Mississippi, and thereby indirectly acquire First National Bank, Rosedale, Mississippi.

B. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

I. Michael J. Klaassen, Trustee of the Theodore K. Klaassen Revocable Living Trust and the Talma B. Klaassen Revocable Living Trust, all of Wichita, Kansas; to acquire an additional 65.19 percent, for a total of 66.58 percent, of the voting shares of Chisholm Trail Financial Corporation, Wichita, Kansas, and thereby indirectly acquire First National Bank, Derby, Kansas, and Chisholm Trail State Bank, Wichita, Kansas.

C. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. Wilma McKnight, Throckmorton, Texas; to acquire an additional 14.59 percent, for a total of 32.99 percent, and Nan McKinney Daws, Wichita Falls, Texas, to acquire an additional 5.99 percent, for a total of 27.79 percent of the voting shares of Throckmorton Bancshares, Inc., Throckmorton, Texas, and thereby indirectly acquire First National Bank, Throckmorton, Texas.

Board of Governors of the Federal Reserve System, November 27, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–30783 Filed 12–3–96; 8:45 am]

BILLING CODE 6210–01–F

## Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act, including whether the acquisition of the nonbanking company can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices" (12 U.S.C. 1843). Any request for a hearing must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 27, 1996.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. Bando McGlocklin Capital Corporation, Pewaukee, Wisconsin; to become a bank holding company by acquiring 100 percent of the voting shares of Investors Bank, Pewaukee, Wisconsin, a de novo bank.

In connection with this application, Applicant also has applied to continue to engage through Bando McGlocklin Small Business Lending Company, Pewaukee, Wisconsin, and Bando McGlocklin Investment Corporation, Pewaukee, Wisconsin, in making and servicing loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

2. CH and JD Byrum, LLC, Indianapolis, Indiana; to acquire 52.4 percent of the voting shares of American State Corporation, Lawrenceburg, Indiana, and thereby indirectly acquire American State Bank, Lawrenceburg, Indiana.

B. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. International Bancorporation, Golden Valley, Minnesota; to merge with Carlton County Bancorporation, Inc., Cloquet, Minnesota, and thereby indirectly acquire City National Bank of Cloquet, Cloquet, Minnesota.

C. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

*I. First Team Resources Corporation*, Derby, Kansas; to become a bank holding company by acquiring 97.12 percent of the voting shares of First National Bank, Derby, Kansas.

D. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-

1. Rotan Bancshares, Inc., Rotan, Texas, and Rotan Delaware Bancshares, Inc., Dover, Delaware; to become bank holding companies by acquiring 100 percent of the voting shares of First National Bank, Rotan, Texas.

Board of Governors of the Federal Reserve System, November 27, 1996.
Jennifer J. Johnson, *Deputy Secretary of the Board.*[FR Doc. 96–30784 Filed 12–3–96; 8:45 am]
BILLING CODE 6210–01–F

## Notice of Proposals To Engage in Permissible Nonbanking Activities or To Acquire Companies That are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of

interests, or unsound banking practices" (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 17, 1996.

A. Federal Reserve Bank of Cleveland (R. Chris Moore, Senior Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. CoBancorp, Inc., Elyria, Ohio; to acquire Jefferson Savings Bank, West Jefferson, Ohio, and thereby engage in permissible savings association activities, pursuant to § 225.25(b)(9) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, November 27, 1996.
Jennifer J. Johnson, *Deputy Secretary of the Board.*[FR Doc. 96–30785 Filed 12–3–96; 8:45 am]
BILLING CODE 6210–01–F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **National Institutes of Health**

National Institute of Allergy and Infectious Diseases; Notice of Meeting: AIDS Research Advisory Committee, NIAID

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the AIDS Research Advisory Committee, National Institute of Allergy and Infectious Diseases, on January 24, 1997 in Conference Rooms E1/E2, Natcher Building on the campus of the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland.

The entire meeting will be open to the public from 8 a.m. until adjournment. The AIDS Research Advisory Committee (ARAC) advises and makes recommendations to the Director, National Institute of Allergy and Infectious Diseases, on all aspects of research on HIV and AIDS related to the mission of the Division of AIDS (DAIDS).

The Committee will provide advice on scientific priorities, policy, and program balance at the Division level. The Committee will review the progress and productivity of ongoing efforts, and identify critical gaps/obstacles to progress. Attendance by the public will be limited to space available.

Ms. Jean S. Noe, Acting Executive Secretary, AIDS Research Advisory Committee, DAIDS, NIAID, NIH, Solar Building, Room 2A20, telephone 301–496–0545, will provide a summary of the meeting and a roster of committee members upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Noe in advance of the meeting.

(Catalog of Federal Domestic Assistance Program Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health)

Dated: November 25, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–30786 Filed 12–3–96; 8:45 am] BILLING CODE 4140–01–M

National Institute of Allergy and Infectious Diseases; Notice of Meetings: National Advisory Allergy and Infectious Diseases Council; Acquired Immunodeficiency Syndrome Subcommittee; Allergy and Immunology Subcommittee; Microbiology and Infectious Diseases Subcommittee

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the National Advisory Allergy and Infectious Diseases Council, National Institute of Allergy and Infectious Diseases, and its subcommittees on January 23–24, 1997. Meetings of the Council, NAAIDC Allergy and Immunology Subcommittee, NAAIDC Microbiology and Infectious Diseases Subcommittee and the NAAIDC Acquired Immunodeficiency Syndrome Subcommittee will be held at the National Institutes of Health, Building 31C, Bethesda, Maryland.

The meeting of the full Council will be open to the public on January 23 in Conference Room 10 from approximately 1 p.m. until 3:30 p.m. for opening remarks of the Institute Director, discussion of procedural matters, Council business, and a report from the Institute Director which will include a discussion of budgetary matters. The primary program will include a discussion of the On-Line Review Pilot Program, an overview of reinvention and review issues being undertaken within the Division of Research Grants, and a presentation on emerging infectious diseases.

On January 24 the meetings of the NAAIDC Allergy and Immunology Subcommittee and NAAIDC Microbiology and Infectious Diseases Subcommittee will be open to the public from 8:30 a.m. until adjournment. The subcommittees will meet in Building 31C, conference rooms 9 and 10 respectively.

The meeting of the NAAIDC Acquired Immunodeficiency Syndrome Subcommittee will be open to the public from 8 until adjournment, on January 24. The subcommittee will meet in Conference Rooms E1/E2 at the Natcher Building.

In accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92–463, the meeting of the NAAIDC Acquired Immunodeficiency Syndrome Subcommittee, NAAIDC Allergy and Immunology Subcommittee and the NAAIDC Microbiology and Infectious Diseases Subcommittee will be closed to the public for approximately four hours for review, evaluation, and discussion of individual grant applications. It is anticipated that this will occur from 8:30 a.m. until approximately 1 p.m. on January 23, in conference rooms 8, 9 and 10 respectively. The meeting of the full Council will be closed from 4 p.m. until recess on January 23 for the review, discussion, and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Claudia Goad, Committee
Management Officer, National Institute
of Allergy and Infectious Diseases, Solar
Building, Room 3C26, National
Institutes of Health, Bethesda, Maryland
20892, 301–496–7601, will provide a
summary of the meeting and a roster of
committee members upon request.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
contact Ms. Goad in advance of the
meeting.

Dr. Lawrence Deyton, Acting Director, Division of Extramural Activities, NIAID, NIH, Solar Building, Room 3C20, 6003 Executive Boulevard, Rockville, Maryland 20892, telephone 301–496–7291, will provide substantive program information.

(Catalog of Federal Domestic Assistance Program Nos. 93.855 Immunology, Allergic and Immunologic Diseases Research, 93.856,